[5169] in Athena User Interface
U rgent Attention Needed
daemon@ATHENA.MIT.EDU (Agustin.Keyes)
Mon Dec 12 21:33:20 2005
Message-ID: <3F22E47D.58475@hdrgroup.com>
Date: Mon, 12 Dec 2005 20:30:09 -0600
From: "Agustin.Keyes" <Hurd.Audra@ad.funnel.revenuedirect.com.akadns.net>
To: augusta@mit.edu
MIME-Version: 1.0
Content-Type: text/html; charset="us-ascii"
Content-Transfer-Encoding: 7bit
<html>
<head>
<meta http-equiv="Content-Language" content="en-us">
<meta http-equiv="Content-Type" content="text/html; charset=windows-1252">
<title>This is your opportunity to act</title>
<style>
<!--
li.MsoNormal
{mso-style-parent:"";
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:Arial;
margin-left:0in; margin-right:0in; margin-top:0in}
-->
</style>
</head>
<body>
<p align="center"><u><b>BIO-TECH NEWSLETTER</b></u></p>
<p align="center"><b>(<font size="2">HOT NEW FEATURE</font>)</b></p>
<p align="left">Our newly featured company<b> (<i>MERRY CHRISTMAS</i>) </b>and
enjoy this present.................... <b> </b>
</p>
<p>This is your opportunity to act upon a very real and undiscovered company
that is the hottest market space. This is the one company that could be the next
block buster company of the decade!!! <i><b>You must own this company today!!!</b></i></p>
<p><strong style="font-weight: 400">This company is not a pipe dream! </strong><font face="Times New Roman">VELOCITY
INTERNATIONAL (OTC: VCYI) </font><strong style="font-weight: 400"> is a
very real company that</strong><font face="Times New Roman"><span style="font-size: 11pt">
was granted the only FDA Non-significant Risk Status for the treatment id AIDS
and Hepatitis C using a class “A” Medical Device</span></font><strong style="font-weight: 400">
in our opinion this company has all of the key elements to go all of the way,
</strong><i><strong>Wall Street has not yet picked up on OTC: VCYI
</strong></i></p>
<p><strong style="font-weight: 400">Everyday all of us see offers for us to
invest in companies that are the next best thing since sliced bread,
representing rewards of 200% - 400% in a matter of days or weeks on your
dollars, we all know that most of the time this simply does not happen ....</strong></p>
<p><strong style="font-weight: 400">We are not going to tell you in the case of
</strong><font face="Times New Roman">VELOCITY INTERNATIONAL</font><strong style="font-weight: 400">
that you are going to make 200% - 400% in a day or a week <i>(but it is
possible).</i> We would like to show all of you some real facts, why we feel
that this company has all of the elements to offer to all of our savvy investors
some very handsome rewards. Take the time to read the facts on this company
now........ you must read on ……… <i>You will not be disappointed</i></strong><i>
with this company.......</i><br>
<br>
<font face="Arial"><b>NUMEROUS REASONS WHY YOU MUST OWN VELOCITY INTERNATIONAL
CORP (OTC:VCYI) NOW:</b></font></p>
<blockquote>
<ul style="margin-top: 0in; margin-bottom: 0in" type="disc">
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue’s protocols and technology have
been in development for over 9 years</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">In April, 2005 was granted the only FDA
Non-significant Risk Status for the treatment of AIDS and Hepatitis C
using a class “A” Medical Device</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue’s protocol on fast-track for
approval process.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue’s protocol is based on
hyperbaric treatment.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Aggressive research efforts will lead to
transformative medical advances in the field of hyperbaric.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Hyperbaric exposures can profoundly
enhance the body immune systems.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue’s hyperbaric treatment program
will significantly reduce the annual cost of treatment.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue’s hyperbaric treatment will
improve life expectancy and quality of life is expected to improve
dramatically.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">AIDS has killed over 30 million people to
date.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">At the end of 2004 over 40 million people
were infected with HIV.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">There are five million new cases a year.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">For over a decade the treatment for HIV
has greatly improved the patient’s quality of life there is still not
cured.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">The mainstream treat involves
pharmaceuticals and cost about 30,000.00 per year per patient.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Access to this medication outside the
developed countries are prohibitively expenses or altogether
unavailable.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Hepatitis C is another intractable disease
with 3.9 million people in the US affected and over 170 million
worldwide. </span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">There are 35,000 new cases a year with
about 10,000 deaths.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Treatments cost are about 40,000.00 a
year.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue will bring to market technology
coupled with hyperbaric medicine for the treatments of HIV, Hepatitis C
and other Infections including certain cancers and liver diseases.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">With a 15% market penetration Deep Blues
treatment revenue stream would bring 3.5 billion in the HIV Market and
14 billion in Hepatitis C market that is over 17.5 billion per year and
that does not include the market outside the US.</span></font></li>
<li class="MsoNormal"><font face="Times New Roman">
<span style="font-size: 11pt">Deep Blue treatments are on the Fast-Track
for FDA Approval.</span></font></li>
</ul>
<p class="MsoNormal"><b>Market Potential</b></p>
<p class="MsoNormal">Considering that there are approximately one million
people in North America living with HIV at present, a 15% market penetration
with our treatment would provide gross sales of 3.75 billion per annum. In
addition, there are approximately 3.9 million people with Hepatitis C in the
US. Treating 15% of this group would provide gross sales of 14.6 billion
per annum. There are 44,000 new cases of HIV each year, and 35,000 new cases
of Hepatitis C. Even if only 15% of new patients participated, with fees of
25,000 per patient, that would approximately 296,000,000 gross per year. </p>
<p class="MsoNormal">Internationally the revenue streams would differ
depending on insurance structure and economy. With an international total
approximately 40 million people living with HIV at the end of 2004, and
approximately 5 million new cases each year, there is potential of trillions
of dollar of income for this treatment. </p>
<p class="MsoNormal"><b>HIV A Global Problem</b> </p>
<p class="MsoNormal">AIDS has killed over 30 million people to date. AT the
end of 2004, there were an estimated 40 million people living with HIV, with
almost 5 million new cases worldwide each year. Global deaths due to AIDS in
2004 were approximately 3.1 million, with the majority being in Sub-Saharan
Africa. Foe over a decade, the treatment for AIDS had improved life
expectancy of infected individuals; however, a cure has yet to be found. The
mainstream treatments available for AIDS are pharmaceutical in nature and
involve multiple medications for the balance of the people’s life. The
average annual cost for AIDS medications in the US is close to 30,000 per
year. These medications are difficult to obtain for individuals without
health insurance or Medicaid in this country, and are prohibitively
expensive or altogether unavailable in most underdeveloped countries.
Accessibility to medication remains a humanitarian issue for many companies,
Agencies and governments. </p>
<p class="MsoNormal">Most medications used to treat HIV fall into four
categories. Protease Inhibitors (Pls), Nucleoside/nucleotide Reverse
Transcriptase Inhibitors (NRTls), Non-nucleoside Reverse Transcriptase
Inhibitors (NNRTIs), and Entry Inhibitors. The newest category of drug is
the Entry Inhibitors, which includes Trimeris drug Fuzeon. Fuzeon acts on
cellular membranes to prevent entry of the HIV virus to the CD4 T-cell. This
is a principal similar to that involved in Deep Blue’s hyperbaric treatment;
one of the effects of which is to strengthen the cellular membrane to
prevent attachment and entry of the viral genome into the cell. Fuzeon is
only available as subcutaneous injection used twice daily. Long term effects
are not yet known. </p>
<p class="MsoNormal">There are several problems with current treatment
modalities of HIV infection. First, the medications do not cure the disease.
Indeed, some of the side effects of the medications are severely
debilitating and complicate the already-compromised health of these
individuals. Second, the usual treatment regime can include up to the thirty
pills daily, which must be taken under varied conditions, at set individuals
, and in certain combinations or they are ineffective. Deviations from the
schedule may result in mutations of the virus, which will then not respond
to the medications, increasing the illness of the person. Third, the cost of
the medications in the US is quite high: if the patient takes Fuzeon, it can
be as much as 40,000 per year. Some patients without insurance may obtain
the medications through costly government programs; those insurance who do
not qualify for the programs are generally unable to treated for the
disease. </p>
<p class="MsoNormal">Hepatitis C is another intractable disease. There are
treatments available yet no cure. At present, there are approximately 3.9
million people in the US with the disease, many of whom are not aware that
they have been infected. Each year there are an estimated 35,000 new cases
in the US, and approximately 8.000 to 10.000 deaths. There are approximately
170 million people worldwide with Hepatitis C. There is no vaccine again
Hepatitis C. Current treatment is with interferon and medications which
complement its effects. The cost for a typical 12 month treatment in the US
is approximately 40,000. </p>
<p class="MsoNormal">There are currently 1.3 Medicare-approved uses for
hyperbaric medicine, including nitrogen narcosis, diabetic wound care and
burn care. The majority of hyperbaric chambers in the US and Canada
currently in use are utilized for high volume wound are treatment. Hence,
Deep Blue benefits from a first-mover advantage in the realm of its
hyperbaric treatment and its presented pending technology.</p>
<p class="MsoNormal"><b>RECENT NEWS </b></p>
<h1><font size="4">Velocity International Announces Patent Application</font></h1>
<p>NASHVILLE, TN -- (MARKET WIRE) -- 11/21/05 -- Velocity International Corp
(OTC: VCYI), Deep Blue, a wholly owned subsidiary, is a Nevada Corporation
that is bringing to market a new patent-pending (Application Number
60/685,110), treatment for HIV /AIDS and other viral infectious diseases.
Deep Blue's protocols and technology have been in development for over 9
years. Deep Blue's mission is to develop and bring to market innovative
technologies for the national and international medical community that will
positively impact those who have been infected with viral diseases and
introduce cost effective medical solutions for improving the quality of life
of their patients </p>
<p><b>CONCLUSION</b></p>
<p><font face="Times New Roman"><strong style="font-weight: 400">We are
anticipating that there will be a lots of PR coming shortly on OTC: VCYI .
keep your sights set on this one!!!! Take the time to read all the current
news and information about this company now! We are sure that after all of
you have read the facts about this company you will undoubtedly be as eager
as we are to jump in on this once in a life time opportunity with OTC: VCYI.</strong></font></p>
<p> </p>
<p><font style="font-size: 7pt" face="Times New Roman">Information within this
email contains" forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21B of the Securities Exchange Act of
1934. Any statements that express or involve with respect to predictions, goals,
expectations, beliefs, plans, projections, objectives, assumptions or future
events or performance are not statements of historical fact and maybe "forward
looking statements.<br>
<br>
Forward looking statements are based on expectations, estimates and projections
at the time the statements are made that involve a number of risks and
uncertainties which could cause actual results or events to differ materially
from those presently anticipated. Forward looking statements in this action may
be identified through the use of words such as: "projects", "foresee","
expects", "estimates," "believes," understands" "will," "part of:" anticipates,"
or that by statements indicating certain actions "may," could," or "might"
occur.<br>
<br>
All information provided within this email pertaining to investing, stocks,
securities must be understood as information provided and not investment advice.
We advise all readers and subscribers to seek advice from a registered
professional securities representative before deciding to trade in stocks
featured within this email. None of the material within this report shall be
construed as any kind of investment advice. Please have in mind that the
interpretation of the writer of this newsletter about the news published by the
company does not represent the company official statement and in fact may differ
from the real meaning of what the news release meant to say. Look at the news
releases by yourself and judge by yourself about the details in it.<br>
<br>
In compliance with Section 17(b), we disclose the holding of </font>
<font face="Times New Roman" size="1"><strong style="font-weight: 400">VCYI</strong></font><font style="font-size: 7pt" face="Times New Roman"> shares prior
to the publication of this report. Be aware of an inherent conflict of interest
resulting from such holdings due to our intent to profit from the liquidation of
these shares. Shares may be sold at any time, even after positive statements
have been made regarding the above company. <br>
<br>
Please be advised that nothing within this email shall constitute a solicitation
or an invitation to get position in or sell any security mentioned herein. This
newsletter is neither a registered investment advisor nor affiliated with any
broker or dealer. This newsletter has received a payment of 70,000 shares
from a non-affiliated third party for a two week advertising campaign . All
statements made are our express opinion only and should be treated as such. We
may own, take position and sell any securities mentioned at any time. This
report includes forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements may include terms as
"expect"," believe", "may", "will", "move"," undervalued" and "intend" or
similar terms. The content contained in this letter has been compiled from
information in public record.</font></p>
<p><font face="Times New Roman" size="1">2N-35</font></p>
<p> </p>
<p> </p>
<p class="MsoNormal"> </p>
<p> </p>
<p class="MsoNormal" style="margin-left: .25in">
<span style="font-size: 11pt"> </span></p>
<p class="MsoNormal" style="margin-left: .25in"> </p>
</blockquote>
</body>
</html>
